Generic Name and Formulations:
Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free.
Company:
Teva Pharmaceuticals
In combination with other chemotherapeutic agents for Wilms' tumor.
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Antimicrotubule agent.
Demyelinating form of Charcot-Marie-Tooth syndrome.
For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Single-use vials (1mL, 2mL)—1
In combination with other chemotherapeutic agents for rhabdomyosarcoma.
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Antimicrotubule agent.
Demyelinating form of Charcot-Marie-Tooth syndrome.
For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Single-use vials (1mL, 2mL)—1
In combination with other chemotherapeutic agents for neuroblastoma.
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Antimicrotubule agent.
Demyelinating form of Charcot-Marie-Tooth syndrome.
For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Single-use vials (1mL, 2mL)—1
Acute leukemia. In combination with other chemotherapeutic agents for Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, diffuse types).
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Antimicrotubule agent.
Demyelinating form of Charcot-Marie-Tooth syndrome.
For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Single-use vials (1mL, 2mL)—1